20 years of cardiac resynchronization therapy

Journal of the American College of Cardiology

Volumn 64, Issue 10, 2014, Pages 1047-1058

  Leyva, Francisco ^a   Nisam, Seah ^b   Auricchio, Angelo ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Nisam Consultancy SPRL   (Belgium)

^c DIVISION OF CARDIOLOGY   (Switzerland)

Author keywords

Artificial; Atrial fibrillation; Cardiac resynchronization therapy; Defibrillators; Electrophysiology; Heart failure; Implantable; Pacemaker; Ventricular remodeling

Indexed keywords

ATRIOVENTRICULAR BLOCK; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CONGESTIVE HEART FAILURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEVICE THERAPY; ECHOCARDIOGRAPHY; EXERCISE; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART PRELOAD; HEART VENTRICLE PACING; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QRS COMPLEX; QUALITY OF LIFE; REVIEW; ARTIFICIAL; DEFIBRILLATOR; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; IMPLANTABLE; MALE; METHODOLOGY; MORTALITY; PACEMAKER; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL; TIME; TREATMENT OUTCOME;

ARTIFICIAL; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS; ELECTROPHYSIOLOGY; HEART FAILURE; IMPLANTABLE; PACEMAKER; VENTRICULAR REMODELING;

CARDIAC RESYNCHRONIZATION THERAPY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84908212735     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.06.1178     Document Type: Review

References (93)

1. Wiggers C. The muscular reactions of the mammalian ventricles to artificial surface stimuli. Am J Physiol 1925;73:346-78.
2. Bakker P, Meijburg H, de Jonge N, et al. Beneficial effects of biventricular pacing in congestive heart failure (abstr). Pacing Clin Electrophysiol 1994;17:820.
3. Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol 1994;17:1974-9.
4. Grines CL, Bashore TM, Boudoulas H, et al. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. Circulation 1989;79: 845-53.
5. Prinzen FW, Augustijn CH, Arts T, et al. Redistribution of myocardial fiber strain and blood flow by asynchronous activation. Am J Physiol 1990;259:H300-8.
6. Befeler B, Berkovits BV, Aranda JM, et al. Programmed simultaneous biventricular stimulation in man, with special reference to its use in the evaluation of intraventricular reentry. Eur J Cardiol 1979;9:369-78.
7. de Teresa E, Chamorro J, Pulpon L, et al. An even more physiological pacing: changing the sequence of ventricular activation. In: Steinbach K, Laskovics A, editors. Proceedings of the 7th World Symposium on Cardiac Pacing. Darmstadt, Germany: Steinkopff-Verlag, 1983: 395-401.
8. Bakker PF, Meijburg HW, de Vries JW, et al. Biventricular pacing in end-stage heart failure improves functional capacity and left ventricular function. J Interv Card Electrophysiol 2000;4: 395-404.
9. Daubert JC, Ritter P, Le Breton H, et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol 1998;21:239-45.
10. Auricchio A, Klein H, Tockman B, et al. Transvenous biventricular pacing for heart failure: can the obstacles be overcome? Am J Cardiol 1999;83: 136D-42D.
11. Leclercq C, Gras D, Le Helloco A, et al. Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing. Am Heart J 1995;129:1133-41.
12. Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 1999;99:2993-3001.
13. Auricchio A, Ding J, Spinelli JC, et al. Cardiac resynchronization therapy restores optimal atrioventricular mechanical timing in heart failure patients with ventricular conduction delay. J Am Coll Cardiol 2002;39:1163-9.
14. Cazeau S, Leclercq C, Lavergne T, et al., for the Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.N Engl J Med 2001;344:873-80.
15. Auricchio A, Stellbrink C, Sack S, et al., for the Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002;39:2026-33.
16. Abraham WT, Fisher WG, Smith AL, et al., for the MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
17. Fung JW, Yu CM, Chan JY, et al. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol 2005;96: 728-31.
18. Young JB, Abraham WT, Smith AL, et al., for the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003;289:2685-94.
19. Bristow MR, Saxon LA, Boehmer J, et al., for the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure. N Engl J Med 2004;350: 2140-50.
20. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007;115: 204-12.
21. Cleland JG, Daubert JC, Erdmann E, et al., for the Cardiac Resynchronization-Heart Failure (CARE-HF) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352: 1539-49.
22. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003;42:1454-9.
23. Abraham WT, Young JB, Leon AR, et al., for the Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverterdefibrillator, and mildly symptomatic chronic heart failure. Circulation 2004;110:2864-8.
24. Moss AJ, Hall WJ, Cannom DS, et al., for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heartfailure events. N Engl J Med 2009;361:1329-38.
25. Linde C, Abraham WT, Gold MR, et al., for the REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-43.
26. Tang AS, Wells GA, Talajic M, et al., for the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-95.
27. Linde C, Gold MR, Abraham WT, et al., for the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction Study Group. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013;34:2592-9.
28. Wilkoff BL, Cook JR, Epstein AE, et al., for the Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular back-up pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288:3115-23.
29. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al., for the MOde Selection Trial Investigators. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003;107:2932-7.
30. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF study. Pacing Clin Electrophysiol 2007;30:S23-30.
31. Curtis AB, Worley SJ, Adamson PB, et al., for the Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;368:1585-93.
32. Funck RC, Blanc JJ, Mueller HH, et al., for the BioPace Study Group. Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the 'Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)' study. Europace 2006;8:629-35.
33. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am J Cardiol 2003;91: 2D-8D.
34. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation In Cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-8.
35. Leclercq C, Walker S, Linde C. Comparative effects of permanent biventricular and rightuniventricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23:1780-7.
36. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). J Am Coll Cardiol HF 2013;1:500-7.
37. Yu C-M, Lin H, Zhang Q, et al. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart 2003;89: 54-60.
38. Yu CM, Chan YS, Zhang Q, et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol 2006;48:2251-7.
39. Achilli A, Sassara M, Ficili S, et al. Longterm effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and "narrow" QRS. J Am Coll Cardiol 2003;42: 2117-24.
40. Foley PW, Patel K, Irwin N, et al. Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. Heart 2011;97:1041-7.
41. Thibault B, Harel F, Ducharme A, et al., for the LESSER-EARTH Investigators. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation 2013; 127:873-81.
42. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369:1395-405.
43. Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010;122:2660-8.
44. Suzuki H, Shimano M, Yoshida Y, et al. Maximum derivative of left ventricular pressure predicts cardiac mortality after cardiac resynchronization therapy. Clin Cardiol 2010;33: E18-23.
45. Kamdar R, Frain E, Warburton F, et al. A prospective comparison of echocardiography and device algorithms for atrioventricular and interventricular interval optimization in cardiac resynchronization therapy. Europace 2010;12: 84-91.
46. Martin DO, Lemke B, Birnie D, et al., for the Adaptive CRT Study Investigators. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm 2012;9:1807-14.
47. Barth AS, Aiba T, Halperin V, et al. Cardiac resynchronization therapy corrects dyssynchronyinduced regional gene expression changes on a genomic level. Circ Cardiovasc Genet 2009;2: 371-8.
48. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
49. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90:1765-73.
50. Pitt B, Zannad F, Remme WJ, et al., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
51. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 2005;112:1580-6.
52. Myers J, Gullestad L, Vagelos R, et al. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. Am Heart J 2000;139:78-84.
53. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro-and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
54. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J 2007;153:105-12.
55. Chalil S, Foley PW, Muyhaldeen SA, et al. Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace 2007;9: 1031-7.
56. Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 2012;60:1659-67.
57. Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts mortality and morbidity following cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol 2007;50:243-52.
58. Arshad A, Moss AJ, Foster E, et al., for the MADIT-CRT Executive Committee. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011;57:813-20.
59. Leyva F, Foley PW, Chalil S, et al. Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol 2011;34:82-8.
60. Chung E, Leon A, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) Trial. Circulation 2008;117:2608-16.
61. Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012;59:1509-18.
62. Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ Heart Fail 2013;6:427-34.
63. Leyva F, Foley P, Chalil S, et al. Cardiac resynchronization therapy guided by late gadoliniumenhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011;13:29-38.
64. Kuijpers NH, Hermeling E, Bovendeerd PH, et al. Modeling cardiac electromechanics and mechanoelectrical coupling in dyssynchronous and failing hearts: insight from adaptive computer models. J Cardiovasc Transl Res 2012;5: 159-69.
65. White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol 2006;48:1953-60.
66. Wong JA, Yee R, Stirrat J, et al. Influence of pacing site characteristics on response to cardiac resynchronization therapy. Circ Cardiovasc Imaging 2013;6:542-50.
67. Duckett SG, Ginks M, Shetty AK, et al. Invasive acute hemodynamic response to guide left ventricular lead implantation predicts chronic remodeling in patients undergoing cardiac resynchronization therapy. J Am Coll Cardiol 2011; 58:1128-36.
68. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;34:3547-56.
69. Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012; 126:822-9.
70. Daubert C, Gold MR, Abraham WT, et al., for the REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009;54:1837-46.
71. Zareba W, Klein H, Cygankiewicz I, et al., for the MADIT-CRT Investigators. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;123: 1061-72.
72. Kronborg MB, Albertsen AE, Nielsen JC, et al. Long-term clinical outcome and left ventricular lead position in cardiac resynchronization therapy. Europace 2009;11:1177-82.
73. Singh JP, Klein HU, Huang DT, et al. Left Ventricular Lead Position and Clinical Outcome in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) Trial. Circulation 2011;123: 1159-66.
74. Chalil S, Stegemann B, Muhyaldeen S, et al. Effect of posterolateral left ventricular scar on mortality and morbidity following cardiac resynchronization therapy. Pacing Clin Electrophysiol 2007;30:1201-9.
75. Leclercq C, Gadler F, Kranig W, et al. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure. J Am Coll Cardiol 2008; 51:1455-62.
76. Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004;109:1133-9.
77. Ploux S, Lumens J, Whinnett Z, et al. Noninvasive electrocardiographic mapping to improve patient selection for cardiac resynchronization therapy: beyond QRS duration and left bundle branch block morphology. J Am Coll Cardiol 2013; 61:2435-43.
78. Garrigue S, Jais P, Espil G, et al. for the Comparison of chronic biventricular pacing between epicardial and endocardial left ventricular stimulation using Doppler tissue imaging in patients with heart failure. Am J Cardiol 2001;88: 858-62.
79. Auricchio A, Delnoy PP, Butter C, et al., for the Collaborative Study Group. Feasibility, safety and short-term outcome of leadless ultrasoundbased endocardial left ventricular resynchronization in heart failure patients: results of the Wireless Stimulation Endocardially for CRT (WiSECRT) study. Europace 2014;16:681-8.
80. Fonarow GC, Albert NM, Curtis AB, et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc 2012; 1:16-26.
81. Maggioni AP, Anker SD, Dahlstrom U, et al., for the Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12, 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-84.
82. van Rees JB, de Bie MK, Thijssen J, et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 2011; 58:995-1000.
83. Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007;28:42-51.
84. Noyes K, Veazie P, Hall WJ, et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol 2013;24:66-74.
85. Linde C, Mealing S, Hawkins N, et al., for the REVERSE Study Group. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J 2011;32: 1631-9.
86. Prinzen FW, Vernooy K, De Boeck BW, et al. Mechano-energetics of the asynchronous and resynchronized heart. Heart Fail Rev 2011;16: 215-24.
87. De Boeck BW, Kirn B, Teske AJ, et al. Three-dimensional mapping of mechanical activation patterns, contractile dyssynchrony and dyscoordination by two-dimensional strain echocardiography: rationale and design of a novel software toolbox. Cardiovasc Ultrasound 2008;6:22-34.
88. Mills RW, Cornelussen RN, Mulligan LJ, et al. Left ventricular septal and left ventricular apical pacing chronically maintain cardiac contractile coordination, pump function and efficiency. Circ Arrhythm Electrophysiol 2009;2: 571-9.
89. Agnetti G, Kaludercic N, Kane LA, et al. Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet 2010;3:78-87.
90. Chakir K, Daya SK, Aiba T, et al. Mechanisms of enhanced b-adrenergic reserve from cardiac resynchronization therapy. Circulation 2009;119: 1231-40.
91. Aiba T, Hesketh GG, Barth AS, et al. Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation 2009;119: 1220-30.
92. Potse M, Krause D, Bacharova L, et al. Similarities and differences between electrocardiogram signs of left bundle-branch block and left-ventricular uncoupling. Europace 2012;14 Suppl 5:v33-9.
93. Steendijk P, Tulner SA, Bax JJ, et al. Hemodynamic effects of long-term cardiac resynchronization therapy: analysis by pressure-volume loops. Circulation 2006;113:1295-304.